No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Medy-Tox Inc., a biopharmaceutical company established in 2000 and headquartered in Cheongju, South Korea, develops and distributes a diverse array of medical products. Its offerings include several botulinum toxin treatments: Neuronox, a lyophilized injectable powder, which is utilized for treating foot deformities caused by spasticity in children with cerebral palsy; INNOTOX, a transparent liquid injectable solution aimed at the temporary improvement of moderate to severe glabellar wrinkles; and Coretox, another freeze-dried injectable powder, also formulated for temporarily reducing moderate to severe frown lines. The company also manufactures hyaluronic acid-based dermal fillers, such as Neuramis and Potenfill, which function as tissue-recovering biomaterials. Beyond injectables, Medy-Tox provides various medical devices, including ComfortDual and Recell Ice, designed for tissue coagulation using high-frequency current; Neurajet Plus, an assisting tool for administering other pharmaceuticals; Carewave, which employs low-intensity electromagnetic shockwaves to address erectile dysfunction; and Careveam, an ultraviolet light device for managing skin ailments. Furthermore, the company offers Neurakin cream, a topical treatment for a range of dermatological conditions including acute and chronic eczema, contact and atopic dermatitis, rosacea and perioral dermatitis, herpes zoster, and acne vulgaris. Medy-Tox's products are exported to approximately 60 countries worldwide, with key markets encompassing Japan, Thailand, and Brazil. The company is also collaborating with Dyadic International, Inc. to develop vaccines targeting COVID-19 variants.

• Jiangsu Recbio Technology Co., Ltd.
• BioDlink International Company Limited
• Inhibikase Therapeutics, Inc.
• Polaris Group
• Keros Therapeutics, Inc.
• Shattuck Labs, Inc.
• Fate Therapeutics, Inc.
• Antengene Corporation Limited